Why CRISPR Therapeutics, Editas Medicine, and Beam Therapeutics Dropped This WeekThe Motley Fool • 07/16/21
Beam Therapeutics to Participate in the 2021 William Blair Biotech Focus ConferenceGlobeNewsWire • 07/08/21
The Top 7 Gene-Editing Stocks to Buy for the Biggest Scientific Breakthrough of the CenturyInvestorPlace • 07/01/21
Beam Therapeutics to Participate in the 2021 Jefferies Virtual Healthcare ConferenceGlobeNewsWire • 05/25/21
3 Growth Stocks to Buy That Could Be Bigger Winners Than Bitcoin and DogecoinThe Motley Fool • 05/24/21
Beam Therapeutics Takes $155M In-Process R&D Expense Hit To Bottomline, But Receives Buy Rating From Redburn PartnersBenzinga • 05/11/21
Beam Therapeutics Inc. (BEAM) Reports Q1 Loss, Lags Revenue EstimatesZacks Investment Research • 05/11/21
Beam Therapeutics Presents LNP Formulation Data at ASGCT and Reports First Quarter 2021 Financial ResultsGlobeNewsWire • 05/11/21
Will Beam Therapeutics Inc. (BEAM) Report Negative Q1 Earnings? What You Should KnowZacks Investment Research • 05/04/21
Beam Therapeutics Announces Oral and Poster Presentations at 24th American Society of Gene and Cell Therapy Annual MeetingGlobeNewsWire • 04/27/21
Beam Therapeutics Publishes Data Highlighting Ability to Rationally Design Base Editors for Precise EditingGlobeNewsWire • 04/20/21
Beam Therapeutics Announces Business and Pipeline Progress and Reports Fourth Quarter and Full Year 2020 Financial ResultsGlobeNewsWire • 03/15/21
Beam Therapeutics to Participate in the Barclays 2021 Global Healthcare ConferenceGlobeNewsWire • 03/04/21